Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Neurology, Vol 45, Issue 7 1277-1285, Copyright © 1995 by American Academy of Neurology

ARTICLES

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group


Our previously reported multicenter, blinded, randomized, controlled study of two doses of interferon beta-1b (IFNB) in 372 patients demonstrated a reduction in relapse frequency and severity and in MRI activity. We now report the results of the continuation of that study. The median time on study was 46.0 months for the placebo arm, 45.0 months for 1.6 million international units (MIU), and 48.0 months for 8 MIU. IFNB had a persistent beneficial effect on exacerbation rate and MRI burden of disease and was relatively free of long-term side effects. There was a one-third reduction in exacerbation rate in the 8- MIU treatment arm, compared with placebo, in each of 5 years. Serial annual MRI was done in all patients, and 217 of the patients had either a fourth- or fifth-year scan. There was no significant progression of lesion burden in the 8-MIU arm in each successive year compared with baseline (at 4 years, p = 0.917), whereas a highly significant increase in lesion area occurred in the placebo arm (p = 0.0001). Among the 154 noncompleters, there was no systematic bias recognized that favored either treatment arm for the outcome measures of exacerbation rate, disability, or MRI activity. Dropouts in the placebo group had higher exacerbation rates and accumulation of MRI lesion burden than did dropouts in the other treatment arms, which probably reduced the power of the study to demonstrate treatment effects on these measures in the later years of the trial.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 NEJMHome page
The CAMMS223 Trial Investigators
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
N. Engl. J. Med., October 23, 2008; 359(17): 1786 - 1801.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. S. Goodin, B. A. Cohen, P. O'Connor, L. Kappos, and J. C. Stevens
Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, September 2, 2008; 71(10): 766 - 773.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
J Kraus, K Voigt, A. Schuller, M Scholz, K. Kim, M Schilling, W. Schabitz, P Oschmann, and B Engelhardt
Interferon-{beta} stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro
Multiple Sclerosis, July 1, 2008; 14(6): 843 - 852.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C Gneiss, M Brugger, A Millonig, A Fogdell-Hahn, D Rudzki, J Hillert, T Berger, M Reindl, and F Deisenhammer
Comparative study of four different assays for the detection of binding antibodies against interferon-{beta}
Multiple Sclerosis, July 1, 2008; 14(6): 830 - 836.
[Abstract] [PDF]

Home page
 Mult SclerHome page
M Koch, M Uyttenboogaart, A van Harten, and J De Keyser
Factors associated with the risk of secondary progression in multiple sclerosis
Multiple Sclerosis, July 1, 2008; 14(6): 799 - 803.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Rio, A Rovira, M Tintore, E Huerga, C Nos, N Tellez, C Tur, M Comabella, and X Montalban
Relationship between MRI lesion activity and response to IFN-{beta} in relapsing-remitting multiple sclerosis patients
Multiple Sclerosis, May 1, 2008; 14(4): 479 - 484.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382.
[Abstract] [PDF]

Home page
 Am. J. Neuroradiol.Home page
Y. Duan, P.G. Hildenbrand, M.P. Sampat, D.F. Tate, I. Csapo, B. Moraal, R. Bakshi, F. Barkhof, D.S. Meier, and C.R.G. Guttmann
Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis
AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 340 - 346.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
E. Le Page, E. Leray, G. Taurin, M. Coustans, J. Chaperon, S. P Morrissey, and G. Edan
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 52 - 56.
[Abstract] [Full Text] [PDF]

Home page
 BiometrikaHome page
Y. Huang and J. C. Hsu
Hochberg's Step-Up Method: Cutting Corners Off Holm's Step-Down Method
Biometrika, December 1, 2007; 94(4): 965 - 975.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic
Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study
Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137.
[Abstract] [PDF]

Home page
 Mult SclerHome page
K. Baum, C. O'Leary, F. Coret Ferrer, E. Klimova, L. Prochazkova, J. Bugge, and for the BRIGHT Study Group
Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b
Multiple Sclerosis, November 1, 2007; 13(9): 1153 - 1160.
[Abstract] [PDF]

Home page
 NeurologyHome page
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Neurology, October 9, 2007; 69(15): 1498 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
F. Barkhof, C. H. Polman, E.-W. Radue, L. Kappos, M. S. Freedman, G. Edan, H.-P. Hartung, D. H. Miller, X. Montalban, P. Poppe, et al.
Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol, September 1, 2007; 64(9): 1292 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
K. Cetin, K.L. Johnson, D.M. Ehde, C.M. Kuehn, D. Amtmann, and G.H. Kraft
Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample
Multiple Sclerosis, September 1, 2007; 13(8): 1046 - 1053.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L. Glass-Marmor, T. Paperna, Y. Ben-Yosef, and A. Miller
Chronotherapy using corticosteroids for multiple sclerosis relapses
J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 886 - 888.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
D. Soon, D. Tozer, D. Altmann, P. Tofts, and D. Miller
Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes
Multiple Sclerosis, August 1, 2007; 13(7): 884 - 894.
[Abstract] [PDF]

Home page
 NeurologyHome page
O. Khan
Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. Zivadinov
Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?
Neurology, May 29, 2007; 68(22_suppl_3): S72 - S82.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. L. Arnold
Evidence for neuroprotection and remyelination using imaging techniques
Neurology, May 29, 2007; 68(22_suppl_3): S83 - S90.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A. AL-Sabbagh
Neutralizing antibodies in MS therapy: reviewing the Rebif experience
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 8 - 13.
[Abstract] [PDF]

Home page
 Mult SclerHome page
K. O'Rourke, C. Walsh, G. Antonelli, and M. Hutchinson
Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
Multiple Sclerosis, April 1, 2007; 13(3): 336 - 342.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, March 27, 2007; 68(13): 977 - 984.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
F Gilli, F Hoffmann, A Sala, F Marnetto, M Caldano, P Valentino, L Kappos, A Bertolotto, and R L. Lindberg
Qualitative and quantitative analysis of antibody response against IFN{beta} in patients with multiple sclerosis
Multiple Sclerosis, November 1, 2006; 12(6): 738 - 746.
[Abstract] [PDF]

Home page
 Mult SclerHome page
O Lily, E McFadden, E Hensor, M Johnson, and H Ford
Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment
Multiple Sclerosis, November 1, 2006; 12(6): 808 - 813.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu
Regression to the mean in multiple sclerosis
Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. S. Goodin, N. Koch-Henriksen, and P. S. Sorensen
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Neurology, October 10, 2006; 67(7): 1313 - 1314.
[Full Text] [PDF]

Home page
 NeurologyHome page
J. H. Noseworthy
How much can we learn from long-term extension trials in multiple sclerosis?
Neurology, September 26, 2006; 67(6): 930 - 931.
[Full Text] [PDF]

Home page
 NeurologyHome page
L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Neurology, September 26, 2006; 67(6): 944 - 953.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, E. W. Radue, et al.
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
N. Engl. J. Med., September 14, 2006; 355(11): 1124 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
L L. Mantia, D D'Amico, A Rigamonti, N Mascoli, G Bussone, and C Milanese
Interferon treatment may trigger primary headaches in multiple sclerosis patients
Multiple Sclerosis, August 1, 2006; 12(4): 476 - 480.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
Multiple Sclerosis, June 1, 2006; 12(3): 309 - 320.
[Abstract] [PDF]

Home page
 NeurologyHome page
D.K.B. Li, U. Held, J. Petkau, M. Daumer, F. Barkhof, F. Fazekas, J. A. Frank, L. Kappos, D. H. Miller, J. H. Simon, et al.
MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability
Neurology, May 9, 2006; 66(9): 1384 - 1389.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al.
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
Arch Neurol, April 1, 2006; 63(4): 614 - 619.
[Full Text] [PDF]

Home page
 BrainHome page
M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Brain, March 1, 2006; 129(3): 584 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C Ross, K M Clemmesen, P S Sorensen, N Koch-Henriksen, and K Bendtzen
Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis
Multiple Sclerosis, February 1, 2006; 12(1): 39 - 46.
[Abstract] [PDF]

Home page
 Mult SclerHome page
B A Kallmann, S Fackelmann, K V Toyka, P Rieckmann, and K Reiners
Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis
Multiple Sclerosis, February 1, 2006; 12(1): 58 - 65.
[Abstract] [PDF]

Home page
 NeurologyHome page
T. Wesselius, D. J. Heersema, J. P. Mostert, M. Heerings, F. Admiraal-Behloul, A. Talebian, M. A. van Buchem, and J. De Keyser
A randomized crossover study of bee sting therapy for multiple sclerosis
Neurology, December 13, 2005; 65(11): 1764 - 1768.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
D. Shabas and M. Heffner
Multiple sclerosis management for low-income minorities
Multiple Sclerosis, December 1, 2005; 11(6): 635 - 640.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Haas, M Maas-Enriquez, and H P Hartung
Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years
Multiple Sclerosis, October 1, 2005; 11(5): 562 - 567.
[Abstract] [PDF]

Home page
 Mult SclerHome page
D Mikol, M Lopez-Bresnahan, S Taraskiewicz, P Chang, J Rangnow, and RebijectTM Study Group
A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif(R)) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis
Multiple Sclerosis, October 1, 2005; 11(5): 585 - 591.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al.
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Arch Neurol, October 1, 2005; 62(10): 1519 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J Zajicek
Diagnosis and disease modifying treatments in multiple sclerosis
Postgrad. Med. J., September 1, 2005; 81(959): 556 - 561.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil
Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS
Neurology, July 12, 2005; 65(1): 48 - 55.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. S. Sorensen, N. Koch-Henriksen, C. Ross, K. M. Clemmesen, K. Bendtzen, and the Danish Multiple Sclerosis Study Group
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy
Neurology, July 12, 2005; 65(1): 33 - 39.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
D. R Jeffery, N. Chepuri, D. Durden, and J. Burdette
A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging
Multiple Sclerosis, June 1, 2005; 11(3): 296 - 301.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. R. Schwid, J. Thorpe, M. Sharief, M. Sandberg-Wollheim, K. Rammohan, J. Wendt, H. Panitch, D. Goodin, D. Li, P. Chang, et al.
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis: The EVIDENCE Study
Arch Neurol, May 1, 2005; 62(5): 785 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S. B Patten, G. Francis, L. M Metz, M. Lopez-Bresnahan, P. Chang, and F. Curtin
The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2005; 11(2): 175 - 181.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. H. Polman, L. Kappos, F. Dahlke, R. Graf, K. Beckmann, T. Bogumil, C. Pozzilli, A. J. Thompson, and the European Study Group on Interferon Beta-1b in
Interferon beta-1b treatment does not induce autoantibodies
Neurology, March 22, 2005; 64(6): 996 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Saida, K. Tashiro, Y. Itoyama, T. Sato, Y. Ohashi, Z. Zhao, and the Interferon Beta-1b Multiple Sclerosis Study Gr
Interferon beta-1b is effective in Japanese RRMS patients: A randomized, multicenter study
Neurology, February 22, 2005; 64(4): 621 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
K E. O'Rourke and M Hutchinson
Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns
Multiple Sclerosis, February 1, 2005; 11(1): 46 - 50.
[Abstract] [PDF]

Home page
 NeurologyHome page
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al.
Identifying and treating patients with suboptimal responses
Neurology, December 28, 2004; 63(12_suppl_6): S33 - S40.
[Abstract] [Full Text]

Home page
 NeurologyHome page
A. Langer-Gould, H. H. Moses, and T. J. Murray
Strategies for managing the side effects of treatments for multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S35 - S41.
[Abstract] [Full Text]

Home page
 NeurologyHome page
T. K. Vartanian, S. S. Zamvil, E. Fox, and P. S. Sorensen
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S42 - S49.
[Abstract] [Full Text]

Home page
 Mult SclerHome page
C Espejo, L Brieva, G Ruggiero, J Rio, X Montalban, and E M Martinez-Caceres
IFN-{beta} treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosis
Multiple Sclerosis, December 1, 2004; 10(6): 630 - 635.
[Abstract] [PDF]

Home page
 Mult SclerHome page
M P. Leuschen, M. Filipi, and K. Healey
A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN {beta}-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis
Multiple Sclerosis, December 1, 2004; 10(6): 636 - 642.
[Abstract] [PDF]

Home page
 NeurologyHome page
L. Kappos, B. Weinshenker, C. Pozzilli, A. J. Thompson, F. Dahlke, K. Beckmann, C. Polman, H. McFarland, and for the European and North American Interferon b
Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials
Neurology, November 23, 2004; 63(10): 1779 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
The North American Study Group on Interferon beta-
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
Neurology, November 23, 2004; 63(10): 1788 - 1795.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
T L Vollmer, J T Phillips, A D Goodman, M A Agius, M A Libonati, J L Giacchino, and J S Grundy
An open-label safety and drug interaction study of natalizumab (AntegrenTM) in combination with interferon-beta (Avonex(R)) in patients with multiple sclerosis
Multiple Sclerosis, October 1, 2004; 10(5): 511 - 520.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies
J. Neurol. Neurosurg. Psychiatry, September 1, 2004; 75(9): 1294 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
E M Frohman, K Brannon, S. Alexander, D Sims, J T Phillips, S O'Leary, K Hawker, and M K Racke
Disease modifying agent related skin reactions in multiple sclerosis: prevention, assessment, and management
Multiple Sclerosis, June 1, 2004; 10(3): 302 - 307.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
O Andersen, I Elovaara, M Farkkila, H J Hansen, S I Mellgren, K-M Myhr, M Sandberg-Wollheim, and P Soelberg Sorensen
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcuta